Lyell Immunopharma (LYEL) Return on Sales (2020 - 2026)
Lyell Immunopharma recorded quarterly Return on Sales of 210.34% in Q1 2026, down 0.99% quarter-over-quarter from 208.28% in Q4 2025, and down 13390.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's Return on Sales history runs 7 years deep, the most recent figure standing at 210.34% for Q1 2026.
- In Q1 2026, Return on Sales fell 13390.0% year-over-year to 210.34%; the TTM figure through Mar 2026 stood at 79.0% (down 2677.0% YoY), while the FY2025 annual figure was 71.2%, down 1633.0% from the prior year.
- Return on Sales came in at 210.34% for Q1 2026 at Lyell Immunopharma, down from 208.28% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2022 to a low of 213.95% in Q3 2022.
- A 5-year average of 74.66% and a median of 34.74% in 2024 frame the typical range for Return on Sales.
- Across the five-year window, Return on Sales tumbled 21378 bps in 2022 and soared 19298 bps in 2023, its largest moves.
- Lyell Immunopharma's Return on Sales stood at 0.0% in 2022, then slumped by 1721920 bps to 40.33% in 2023, then slumped by 342 bps to 178.39% in 2024, then dropped by 17 bps to 208.28% in 2025, then dropped by 1 bps to 210.34% in 2026.
- According to Business Quant data, Return on Sales over the past three periods registered 210.34%, 208.28%, and 22.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.00% |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -210.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -210.34% |
| Dec 31, 2025 | -208.28% |
| Sep 30, 2025 | -22.66% |
| Jun 30, 2025 | -54.83% |
| Mar 31, 2025 | -76.44% |
| Dec 31, 2024 | -178.39% |
| Sep 30, 2024 | -13.10% |
| Jun 30, 2024 | -34.74% |
| Mar 31, 2024 | -162.52% |
| Dec 31, 2023 | -40.33% |
| Sep 30, 2023 | -20.97% |
| Jun 30, 2023 | -22.46% |
| Mar 31, 2023 | -8.93% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | -213.95% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -1.23% |
| Dec 31, 2021 | -0.17% |
| Sep 30, 2021 | -0.18% |
| Jun 30, 2021 | -0.24% |
| Mar 31, 2021 | -0.23% |
| Dec 31, 2020 | -0.17% |
| Sep 30, 2020 | -0.33% |
| Jun 30, 2020 | -0.32% |